ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Gain Therapeutics Inc

Gain Therapeutics Inc (GANX)

1.38
0.02
(1.47%)
Closed July 13 4:00PM
1.38
0.00
(0.00%)
After Hours: 7:23PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.38
Bid
1.15
Ask
3.82
Volume
273,476
1.34 Day's Range 1.3902
1.11 52 Week Range 5.33
Market Cap
Previous Close
1.36
Open
1.37
Last Trade Time
Financial Volume
$ 374,020
VWAP
1.3677
Average Volume (3m)
276,957
Shares Outstanding
18,051,979
Dividend Yield
-
PE Ratio
-1.12
Earnings Per Share (EPS)
-1.22
Revenue
55k
Net Profit
-22.11M

About Gain Therapeutics Inc

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applicatio... Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gain Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GANX. The last closing price for Gain Therapeutics was $1.36. Over the last year, Gain Therapeutics shares have traded in a share price range of $ 1.11 to $ 5.33.

Gain Therapeutics currently has 18,051,979 shares outstanding. The market capitalization of Gain Therapeutics is $24.55 million. Gain Therapeutics has a price to earnings ratio (PE ratio) of -1.12.

GANX Latest News

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics...

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1915.96638655461.191.41.113585521.25417071CS
4-0.08-5.479452054791.461.461.115731621.25559443CS
12-1.73-55.62700964633.113.651.112769571.69489191CS
26-1.98-58.92857142863.365.331.112104132.72967265CS
52-3.32-70.63829787234.75.331.111361882.82460931CS
156-8.38-85.86065573779.7610.11.11982954.26784352CS
260-9.84-87.700534759411.2217.931.11963884.88173756CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

GANX Discussion

View Posts
1984ISHERE 1984ISHERE 3 months ago
Market Blood Bath 2.95 LOD =]
👍️0
1984ISHERE 1984ISHERE 3 months ago
2.95 today pickUP opportunity =] as Market Down Huge Blood Everywhere
👍️0
Monksdream Monksdream 3 months ago
GANX under $4
👍️0
Monksdream Monksdream 4 months ago
GANX 10Q due 3/26
👍️0
1984ISHERE 1984ISHERE 5 months ago
Been on fire move 5.29 high
Ok to take a rest
👍️0
Sonic Boom Sonic Boom 5 months ago
Darn, looking good $GANX
👍️0
peteypickem peteypickem 5 months ago
GANX $4.60
👍️0
peteypickem peteypickem 5 months ago
GANX $4.50
👍️0
1984ISHERE 1984ISHERE 6 months ago
1 thing is sure a cure is needed
Stock has fallen back under 4 again
👍️0
1984ISHERE 1984ISHERE 6 months ago
1 thing is sure a cure is needed
Stock has fallen back under 4 again
👍️0
peteypickem peteypickem 6 months ago
$GANX $4 break
👍️0
peteypickem peteypickem 6 months ago
#GANX $3.77
👍️0
peteypickem peteypickem 6 months ago
$GANX $3.66,,
👍️0
peteypickem peteypickem 6 months ago
$GANX $3.50
👍️0
peteypickem peteypickem 6 months ago
$GANX $3.27
👍️0
peteypickem peteypickem 6 months ago
GANX $3.20
👍️0
peteypickem peteypickem 6 months ago
GANX $3.05
👍️0
peteypickem peteypickem 7 months ago
Going higher
👍️0
peteypickem peteypickem 7 months ago
GANX $2.97
👍️0
Alias12345 Alias12345 7 months ago
Holy chit, I'm up over 9% in less than a week and it looks like it just might keep going in this direction with periods of consolidation. Thank you petey for the x post on the 14th. Took a look, bought some last week, very happy.
👍️0
peteypickem peteypickem 7 months ago
GANX $2.77
👍️0
peteypickem peteypickem 7 months ago
GANX $2.69
👍️0
peteypickem peteypickem 7 months ago
GANX $2.55
👍️0
peteypickem peteypickem 7 months ago
GANX —- $2.42
👍️0
peteypickem peteypickem 7 months ago
GANX $2.35
👍️0
1984ISHERE 1984ISHERE 1 year ago
just hovering 4.90-5 range
👍️0
1984ISHERE 1984ISHERE 1 year ago
Holding over 5 - Great News Lately For Longs To Be Excited

https://finance.yahoo.com/news/gain-therapeutics-awarded-chf-2-131500689.html
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
,,,,,,,REVERSAL OF FORTUNE!!! OUCH
👍️0
RoadShowPartner RoadShowPartner 3 years ago
Zoom presentation with Gain Therapeutics (Nasdaq: GANX) this Wednesday, 9/22 @ 4:00pm ET . The CEO Eric Richman will be updating investors and answering questions. Please register to attend the presentation using the link below:

https://www.eventbrite.com/e/gain-therapeutics-inc-webinar-9222021-registration-173949637047?utm_source=eventbrite&utm_medium=email&utm_content=follow_notification&utm_campaign=following_published_event&utm_term=Gain+Therapeutics%2C+Inc.-Webinar+9%2F22%2F2021&aff=ebemoffollowpublishemail
👍️0
ProfitScout ProfitScout 3 years ago
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 17, 2021 (Globe Newswire)

- Conference Dates: September 20-23 -

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22
Time: 1:15 to 1:55 p.m. ET
Presenter: Eric Richman, Chief Executive Officer
Webcast: Registration Link - Click Here
* a replay will be available following the presentation for 90 days
Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with Gain Therapeutics during the respective conference.

For more information about the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, please refer to the conference website.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx(TM) target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

For more information, please visit https://www.gaintherapeutics.com

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for Gain's product candidates, and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include Gain's ability to: make commercially available its products and technologies in a timely manner or at all; enter into strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate and manage its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contacts:

Gain Therapeutics Investor Contact:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576

daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:

Joleen Schultz

Joleen Schultz & Associates

+1 760-271-8150

joleen@joleenschultzassociates.com
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

https://finance.yahoo.com/news/gain-therapeutics-present-oppenheimer-fall-120000696.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0
StockHighAlert- StockHighAlert- 3 years ago
Nice green start here $GANX
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.

https://finance.yahoo.com/news/gain-therapeutics-present-2021-international-202000645.html
👍️0
lockstock31 lockstock31 3 years ago
Running!
👍️0
jedijazz jedijazz 3 years ago
Very nice news. $GANX announced this afternoon that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.
👍️0
ProfitScout ProfitScout 3 years ago
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.

GM1 Virtual Community Conference

Date: Tuesday, September 14th
Time: 2:00pm PT/5:00pm ET
Presenter: Manolo Bellotto, Ph.D., General Manager and President
To register to attend the conference visit https://registration.socio.events/e/gm1

Morquio B, also known as Mucopolysaccharidosis type IV (MPS IV), is a progressive disease mostly impacting the skeleton, caused by mutations in GLB1, the gene that encodes the beta-galactosidase (GLB) enzyme. GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1. In both diseases, these mutations result in the misfolding and subsequent dysfunction of GLB, which leads to toxic substrate accumulation in organs and tissues. Gain is developing allosteric regulators that are designed to decrease toxic substrate accumulation in organs and tissues of patients with Morquio B and GM1 Gangliosidosis in order to potentially provide the first treatment approach for the disease’s neurological symptoms.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

For more information, please visit https://www.gaintherapeutics.com

Forward-Looking Statements
Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for Gain’s product candidates, and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate and manage its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contacts:
Gain Therapeutics Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:
Joleen Schultz
Joleen Schultz & Associates
+1 760-271-8150
joleen@joleenschultzassociates.com

https://www.globenewswire.com/newsroom/ti?nf=ODMyMzQ1NSM0Mzk4MzMwIzUwMDA3MzE2OA==
https://ml.globenewswire.com/media/MTMxYjg2OTktMDc0Yy00NjhkLTk3ZTUtZGRlMzY1OTlhMWE2LTUwMDA3MzE2OA==/tiny/Gain-Therapeutics.png

Source: Gain Therapeutics
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX News! Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease https://finance.yahoo.com/news/gain-therapeutics-inc-announces-positive-112900531.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX announced its financial results as of and for the second quarter June 30, 2021 and highlighted recent corporate accomplishments. https://finance.yahoo.com/news/gain-therapeutics-inc-reports-second-200100807.html

👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update https://finance.yahoo.com/news/gain-therapeutics-inc-reports-second-200100807.html
👍️0
jedijazz jedijazz 3 years ago
$GANX Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets.
https://seekingalpha.com/article/4450667-gain-therapeutics-revolution-in-drug-development-at-venture-like-pricing?utm_source=otcmarkets&utm_medium=referral
👍️0
ProfitScout ProfitScout 3 years ago
$GANX Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug. 19, 2021 12:29 PM ET Gain Therapeutics, Inc. (GANX)
https://seekingalpha.com/article/4450667-gain-therapeutics-revolution-in-drug-development-at-venture-like-pricing?utm_source=otcmarkets&utm_medium=referral

Summary
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets.
Public investors can access this disruptive technology at a venture-like valuation.
A clean balance sheet funds the business until H2 2023, with multiple value inflections expected.
Management has a track record of creating value through pharma partnerships and exits.
Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.
👍️0
ProfitScout ProfitScout 3 years ago
Lots if important developments coming along with GANX as we see described in the latest company update. The CEO sums up nicely in his direct comments:

Eric Richman, Chief Executive Officer of Gain, added, “We are pleased with the progress in advancing our preclinical compounds to the clinic and announced important and compelling data related to our GBA Parkinson’s program. Our SEE-Tx supercomputing platform technology designed to identify novel allosteric binding sites on misfolded proteins continues to meet objectives within our internal pipeline and our external pharmaceutical partnerships. We continue to advance our pipeline towards achieving our mission in redefining drug discovery and developing novel therapies for devastating conditions with significant unmet medical need.”
👍️0
jedijazz jedijazz 3 years ago
$GANX Gain Therapeutics (GANX) Gets a Buy Rating from Oppenheimer https://www.smarteranalyst.com/new-blurbs/gain-therapeutics-ganx-gets-a-buy-rating-from-oppenheimer-2/?mod=mw_quote_news
👍️0
jedijazz jedijazz 3 years ago
Good morning $GANX!
👍️0
ProfitScout ProfitScout 3 years ago
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology
---
Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer’s Disease
---
$43.2 Million in Cash as of June 30, 2021, Provides Runway into Second half of 2023 and a Strong Cash Position to Advance the Company’s Programs

BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced its financial results as of and for the second quarter June 30, 2021 and highlighted recent corporate accomplishments.

Eric Richman, Chief Executive Officer of Gain, added, “We are pleased with the progress in advancing our preclinical compounds to the clinic and announced important and compelling data related to our GBA Parkinson’s program. Our SEE-Tx supercomputing platform technology designed to identify novel allosteric binding sites on misfolded proteins continues to meet objectives within our internal pipeline and our external pharmaceutical partnerships. We continue to advance our pipeline towards achieving our mission in redefining drug discovery and developing novel therapies for devastating conditions with significant unmet medical need.”

Business and Recent Developments

Expansion of Intellectual Property Portfolio. GAIN continues to expand its intellectual property portfolio and in June announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-?glucocerebrosidase (GBA) and galactosylceramidase (GALC) respectively, addressing central nervous system (CNS) and demyelinating disorders such as Parkinson’s Disease, Lewy body dementia and Alzheimer’s Disease.
Signed Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in April to discover new product candidates for the treatment of cancer. The Company will utilize its proprietary SEE-Tx computational platform technology to identify new sites on target proteins for potential use in oncology. The intended deliverables are newly discovered targets or target protein interactions that can then be drugged for therapeutic benefit to intervene on protein misfolding.
Presented at the 26th International Association of Parkinsonism & Related Disorders (IAPRD) World Congress in May. Awarded top 10 best abstract, the presentation highlighted both in vitro & in vivo pre-clinical data demonstrating the potential of STAR compounds for the treatment of GBA1 Parkinson’s Disease. Through partnerships with the Michael J. Fox Foundation and the Silverstein Foundation for Parkinson’s with GBA, GAIN identified two STAR lead candidates (GT-02287 and GT-02329) that can potentially help Parkinson’s patients with GBA1 gene mutations as well as patients whose GCase protein is misfolded due to ageing cellular processes.
Expansion of the leadership team. In June, Terenzio Ignoni Pharm.D., joined the leadership team as SVP Quality and CMC overseeing all manufacturing operations, global CMC regulatory developments, and quality. Dr. Ignoni joins the Company with more than 20 years of experience in the biopharma industry, holding senior positions in multinational pharmaceutical companies including Jazz Pharmaceuticals, Gentium, Vicuron and Zambon Group.
Strong cash position to advance the Company’s programs. As of June 30, 2021, the Company’s cash position was $43.16 million, compared to $7.49 million as of December 31, 2020.
Upcoming 2021 & 2022 Milestones

New Data Release – Top line data from collaboration with University of Maryland School of Medicine on GBA-associated Parkinson’s Disease in IPSC model.
Industry Conference - Full data from collaboration with University of Maryland School of Medicine on GBA-associated Parkinson’s Disease.
Initiate IND-enabling studies 2021 - Gaucher’s / Parkinson’s Disease.
Financial Results

For the second quarter ended June 30, 2021, as compared to the second quarter ended June 30, 2020:

Revenues were $89 thousand compared to $7 thousand
Research and development expenses were $1,794 thousand compared to $439 thousand
General and administrative expenses were $1,810 thousand compared to $100 thousand
Total operating expenses increased to $3,604 thousand, which include the impact of non-cash stock-based compensation and warrants for $536 thousand, compared to $539 thousand
Net loss was $3,557 thousand compared to $543 thousand
GAAP basic and diluted net loss per share was $0.30, compared to basic and diluted net loss per share of $0.27
Revenues were $89 thousand for the three-month period ended June 30, 2021 compared to $7 thousand for the same period of 2020. The increase was primarily attributable to program initiation fees and development services on the first target development program identified under the collaboration agreement with Zentalis Pharmaceuticals.

Research and development expenses of $1,794 thousand for the three-month period ended June 30, 2021 compared to $439 thousand for the same period of 2020, an increase of $1,355 thousand. The increase in research and development expenses was primarily driven by increased program development activities related to the advancement of the Company’s pre-clinical pipeline, as well as increased personnel-related costs resulting from an increase in employee headcount, which includes the impact of non-cash stock-based compensation.

General and administrative expenses were $1,810 thousand for the three-month period ended June 30, 2021 compared to $100 thousand for the same period of 2020, an increase of $1,710 thousand. This increase was primarily due to an increase in personnel-related costs resulting from an increase in employee headcount, which includes the impact of non-cash stock-based compensation, warrants, increase in expenses for legal fees relating to patent and corporate matters, professional fees for accounting and investor relations as we continue to expand our business and build management infrastructure.

As a result of the above, net loss was $3,557 thousand, or ($.30) per share basic and diluted, for the three-month period ended June 30, 2021, compared to $543 thousand or ($.27) per share basic and diluted, for the same period of 2020. The increase in net loss was due to increased research and development expenses, as well as an increase in general and administrative expenses primarily related to investments in the Company’s infrastructure as a publicly traded company.

Cash and cash equivalents were $43.16 million as of June 30, 2021 compared to $7.49 million at December 31, 2020. The increase was primarily the result of the completion of the Company’s initial public offering, from which the Company received aggregate net proceeds of $42.6 million offset by net cash used in operating, investing and payment of deferred offering cost for $6.93 thousand.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

For more information, please visit https://www.gaintherapeutics.com

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval or filing, may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on May 5 2021, as well as other documents that may be filed by the Company from time to time.

New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this earnings release to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this earnings release.



Gain Therapeutics, Inc.
CONSOLIDATED BALANCE SHEETS (unaudited)

June 30, December 31,
2021 2020
Assets
Current assets:
Cash and cash equivalents $ 43,162,583 $ 7,492,910
Restricted cash 10,969 11,371
Accounts receivable 353,166 8,548
Prepaid expenses and other current assets 808,456 257,011
Deferred offering costs $ - $ 1,217,988
Total current assets $ 44,335,174 $ 8,987,828

Non-current assets:
Property and equipment, net 75,063 29,633
Internal-use software 19,357 -
Operating lease - right of use assets 812,410 523,080
Restricted cash 31,100 -
Long-term deposits and other non-current assets 79,924 63,817
Total non-current assets $ 1,017,854 $ 616,530
Total Assets $ 45,353,028 $ 9,604,358

Current liabilities:
Accounts payable 978,393 961,516
Operating lease liability - current 181,306 122,756
Other current liabilities 848,343 767,380
Tax provision 6,837 1,070
Deferred income 370,518 239,483
Loans - short term $ 65,474 $ 22,626
Total current liabilities $ 2,450,871 $ 2,114,831

Non-current liabilities:
Defined benefit pension plan 235,690 171,558
Operating lease liability - non-current 630,902 400,324
Loans - long term $ 646,661 $ 715,656
Total non-current liabilities $ 1,513,253 $ 1,287,538

Stockholders’ equity
Series A Preferred Stock, $0.0001 par value: nil and 1,185,879 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively - 118
Series B Preferred Stock, $0.0001 par value: nil and 2,965,600 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively - 297
Common Stock, $0.0001 par value: 11,876,460 and 7,694,642 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 1,188 354
Additional paid-in capital 54,593,827 13,388,771
Accumulated other comprehensive loss (164,118 ) (152,698 )
Accumulated deficit (7,034,853 ) (3,457,171 )
Loss of the period (6,007,140 ) (3,577,682 )
Total Stockholders’ equity $ 41,388,904 $ 6,201,989
Total Liabilities and Stockholders’ equity $ 45,353,028 $ 9,604,358



Gain Therapeutics, Inc
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

Three Months Ended June 30, Six Months Ended June 30,
2021 2020 2021 2020
Revenues:
Collaboration revenues 81,617 - 81,617 -
Other income 7,556 6,773 12,824 13,047
Total revenues $ 89,173 $ 6,773 $ 94,441 $ 13,047

Operating expenses:
Research and development (1,793,508 ) (438,868 ) (3,215,018 ) (856,127 )
General and administrative (1,810,228 ) (99,970 ) (2,860,903 ) (201,644 )
Total operating expenses (3,603,736 ) (538,838 ) (6,075,921 ) (1,057,771 )

Loss from operations $ (3,514,563 ) $ (532,465 ) $ (5,981,480 ) $ (1,044,724 )

Other income (expense):
Interest income/(expenses), net 5.901 (1,517 ) 7,310 (3,265 )
Foreign exchange loss, net (44,371 ) (4,857 ) (25,832 ) (73,771 )
Loss before income tax $ (3,553,033 ) $ (538,839 ) $ (6,000,002 ) $ (1,121,760 )

Income tax (3,660 ) (4,523 ) (7,138 ) (5,870 )

Net Loss $ (3,556,693 ) $ (543,362 ) $ (6,007,140 ) $ (1,127,630 )

Net loss per shares:
Net loss per share attributable to common stockholders - basic and diluted $ (0.30 ) $ (0.27 ) $ (0.71 ) $ (0.57 )
Weighted average common shares - basic and diluted 11,876,460 1,981,765 8,431,410 1,981,765

Investor & Media Contacts:

Gain Therapeutics Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:
Joleen Schultz
Joleen Schultz & Associates
+1 760-271-8150
joleen@joleenschultzassociates.com

https://www.globenewswire.com/newsroom/ti?nf=ODMwNzM2NCM0MzUzNjg0IzUwMDA3MzE2OA==
https://ml.globenewswire.com/media/MjJhNThiNWQtZDQ2Zi00NzNlLWFiMmMtZTczYTZkMDViMzlkLTUwMDA3MzE2OA==/tiny/Gain-Therapeutics.png
👍️0
jedijazz jedijazz 3 years ago
$GANX LEADING THE DISCOVERY of Allosteric Binding Sites to Create New Medicines

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform.

https://www.gaintherapeutics.com/about/overview.html
👍️0
ProfitScout ProfitScout 3 years ago
Be sure to visit the GANX website which contains a great deal of detailed information on the company's mission, methods and medical applications. The GANX focus on protein misfolding is a very promising new approach to treat some very difficult conditions including Parkinson's Disease.

https://www.gaintherapeutics.com/about/overview.html

LEADING THE DISCOVERY
of Allosteric Binding Sites to Create New Medicines

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform.

By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders.

Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson’s disease. When a protein misfolds, its 3D structure is disrupted and it can no longer function properly. While some treatments are available for these types of disorders, they have significant limitations.

Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
👍️0
jedijazz jedijazz 3 years ago
Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain"), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 - 10. $GANX
👍️0
jedijazz jedijazz 3 years ago
GANX Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Published: Aug. 3, 2021 at 4:51 p.m. ET


BETHESDA, Md., Aug 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain"), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 - 10.

BTIG Virtual Biotechnology Conference
Date: Monday, August 9TH
Time: 11:30 to 11:55 a.m. ET
Presenter: Eric Richman, Chief Executive Officer
Please contact your BTIG representative to listen to the live event and schedule a virtual one-on-one meeting with Gain's management team during the conference.

About BTIG Virtual Biotechnology Conference
The annual August conference will be held virtually. BTIG expects to host more than 120 corporate management teams throughout the two-day, private event which includes thematic panels featuring key opinion leaders, fireside chats, and one-on-one meetings.

For further information, please visit: www.BTIG.com

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx(TM) target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

For more information, visit https://www.gaintherapeutics.com/

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval or filing, may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on May 5 2021, as well as other documents that may be filed by the Company from time to time.

New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this earnings release to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this earnings release.

Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 617-430-7576
daniel@lifesciadvisors.com
👍️0

Your Recent History

Delayed Upgrade Clock